Edward Ludwig, a director at Boston Scientific Corp (BSX, Financial), sold 7,000 shares of the company on February 13, 2024, according to a recent SEC Filing. This transaction was executed at a stock price of $65.03 per share, resulting in a total sale amount of $455,210.
Boston Scientific Corp is a global medical technology leader with a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. The company is known for its innovative devices and therapies that help improve patient outcomes and offer solutions in various medical specialties, including interventional cardiology, cardiac rhythm management, endoscopy, neuromodulation, urology, and pelvic health.
Over the past year, the insider has sold a total of 7,000 shares and has not made any purchases of the company's stock. The recent sale by the insider is part of a trend observed over the past year, where there have been no insider buys and 39 insider sells for Boston Scientific Corp.
On the valuation front, Boston Scientific Corp's shares were trading at $65.03 on the day of the insider's sale, giving the company a market cap of $96.615 billion. The price-earnings ratio stands at 61.64, which is above the industry median of 26.96 but below the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.23, with a GF Value of $52.74, indicating that Boston Scientific Corp is considered modestly overvalued based on its GF Value.
The GF Value is a proprietary intrinsic value estimate from GuruFocus, which takes into account historical trading multiples, a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates provided by Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
